This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/18/2026
Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.
To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.
To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.
Milvexian is a direct, reversible, orally active, small molecule that inhibits the active form of factor XI (FXIa) with high affinity and selectivity.1 In studies, milvexian extended the aPTT in a dose-dependent way and did not impact the prothrombin time (PT).3,5
Perera et al (2022)3 conducted a two-part, randomized, double-blind, placebo-controlled, sequential single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian in healthy subjects. Subjects in the SAD panels received milvexian at doses of 4 mg, 20 mg, 60 mg, 200 mg, 300 mg, and 500 mg whereas subjects in the MAD panels received milvexian at doses of 5 mg, 20 mg, 70 mg, 200 mg, and 500 mg.
Holle et al (2021)4 evaluated the pharmacodynamic effect of milvexian on plasma clot formation and stability in an in vitro study of 5 healthy individuals. Clot formation in normal pooled plasma and plasma was conducted with tissue factor, phospholipids, calcium chloride, and varying concentrations of milvexian or buffer. Fibrinolysis experiments included tissue plasminogen activator. Reactions were monitored by turbidity, and descriptive parameters were analyzed to determine half-maximal effect concentrations.
A literature search of MEDLINE®
| 1 | Perera V, Abelian G, Li D, et al. Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment. Clin Pharmacokinet. 2022;61(10):1405-1416. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 |
Would you like to clear and leave your conversation? Message history will be lost.